ZERO WORLD RESEARCHアミノ酸・有機酸の学術文献データベース

Exploiting branched-chain amino acid metabolism and NOTCH3 expression to predict and target colorectal cancer progression.

分岐鎖アミノ酸代謝とNOTCH3発現の活用による大腸癌進行の予測と標的化 (機械翻訳の邦題)

Frontiers in immunology2024Shen K, Zhu C, Wu J, et al.
研究デザインその他の原著論文
対象ヒト・動物 併記

記録の確認項目

研究デザイン
その他の原著論文
対象
ヒト・動物 併記
出版年
2024
出典
doi.org
抄録の表示
表示あり
出版状態
有効な記録
状態確認日
2026/08/17
収集日
2026/08/03
鮮度
確認期限内
確認段階
自動処理
記録状態
公開

日本語要約(機械生成)

大腸腺癌(COAD)と分岐鎖アミノ酸(BCAA)代謝の関連は不明である。本研究では、LASSO回帰を用いてBCAA代謝関連シグネチャー(BRS)を構築し、COAD患者の免疫特性、腫瘍変異量、免疫療法反応、薬剤感受性を判別した。また、NOTCH3がCOAD組織で過剰発現し、細胞増殖、浸潤、遊走を促進することをin vitroおよびin vivo実験で確認した。BRSは予後と治療反応の予測に有効であり、BCAA代謝とNOTCH3が治療標的となる可能性が示された。

この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。

抄録

Background: The interplay between colon adenocarcinoma (COAD) and branched-chain amino acid (BCAA) metabolism is not fully understood, presenting a crucial area for investigation.Methods: We developed a prognostic model based on BCAA metabolism using the least absolute shrinkage and selection operator (LASSO) regression algorithm. We employed qRT-PCR and Western blot analyses to examine NOTCH3 expression in COAD tissues versus adjacent non-cancerous tissues and various cell lines. We also investigated the impact of NOTCH3 on COAD cell proliferation, invasion, and migration through in vitro and in vivo experiments.Results: Our BCAA metabolism-related signature (BRS) distinguished between different immune features, tumor mutation burdens, responses to immunotherapy, and drug sensitivity among COAD patients. NOTCH3 was found to be overexpressed in COAD, promoting tumor growth as verified through various assays. The model effectively predicted COAD prognosis and patient responses to treatments, underscoring the potential of BCAA pathways as therapeutic targets.Conclusion: The BRS is instrumental in predicting the prognosis and therapeutic response in COAD, with NOTCH3 playing a significant role in the proliferation, invasion and migration of COAD. These findings suggest that targeting BCAA metabolism and NOTCH3 could advance COAD treatment strategies.

MeSH

AdenocarcinomaAmino Acids, Branched-ChainAnimalsBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationColorectal NeoplasmsDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMiddle AgedPrognosisReceptor, Notch3

DOI 10.3389/fimmu.2024.1430352

PMID 39286249

原文・出典を見る →